Online inquiry

IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14011MR)

This product GTTS-WQ14011MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14011MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11029MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ603MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ14671MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ9139MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ1127MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ5860MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ12494MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ12139MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW